IMUX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Immunic Inc

NASDAQ | IMUX

0.89

USD

$0.00

(

0.00%

)

At Close (As of Oct 13, 2025)

$88.64M

Market Cap

-

P/E Ratio

-0.94

EPS

$1.73

52 Week High

$0.56

52 Week Low

HEALTHCARE

Sector

IMUX Chart

Recent Chart
Price Action

IMUX Technicals

Tags:

IMUX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$134K
Total Revenue $0
Cost Of Revenue $134K
Costof Goods And Services Sold $134K
Operating Income -$98M
Selling General And Administrative $18M
Research And Development $80M
Operating Expenses $98M
Investment Income Net -
Net Interest Income $3.4M
Interest Income $3.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $134K
Income Before Tax -$101M
Income Tax Expense -$101M
Interest And Debt Expense -
Net Income From Continuing Operations -$101M
Comprehensive Income Net Of Tax -
Ebit -$101M
Ebitda -$100M
Net Income -$101M

Revenue & Profitability

Earnings Performance

IMUX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $41M
Total Current Assets $39M
Cash And Cash Equivalents At Carrying Value $36M
Cash And Short Term Investments $36M
Inventory -
Current Net Receivables $684K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $3M
Other Non Current Assets -
Total Liabilities $22M
Total Current Liabilities $22M
Current Accounts Payable $7.8M
Deferred Revenue -
Current Debt -
Short Term Debt $740K
Total Non Current Liabilities $264K
Capital Lease Obligations $1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1M
Other Current Liabilities $14M
Other Non Current Liabilities -
Total Shareholder Equity $18M
Treasury Stock -
Retained Earnings -$511M
Common Stock $8K
Common Stock Shares Outstanding $100M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$85M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $134K
Capital Expenditures $264K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$264K
Cashflow From Financing $75M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $77K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$101M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$134K
Total Revenue $0
Cost Of Revenue $134K
Costof Goods And Services Sold $134K
Operating Income -$98M
Selling General And Administrative $18M
Research And Development $80M
Operating Expenses $98M
Investment Income Net -
Net Interest Income $3.4M
Interest Income $3.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $134K
Income Before Tax -$101M
Income Tax Expense -$101M
Interest And Debt Expense -
Net Income From Continuing Operations -$101M
Comprehensive Income Net Of Tax -
Ebit -$101M
Ebitda -$100M
Net Income -$101M

IMUX News

IMUX Profile

Immunic Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on advancing innovative oral immunology therapies aimed at addressing chronic autoimmune and inflammatory diseases. Headquartered in New York, Immunic is dedicated to leveraging its proprietary drug development platform to bring transformative treatments to patients with unmet medical needs. The company's pipeline includes several candidates that are currently undergoing clinical trials, reflecting its commitment to enhancing patient outcomes and driving future growth in the evolving biopharmaceutical landscape.

VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
PFE
-0.30%
$24.70
RR
+7.85%
$6.38
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
IREN
+8.04%
$64.58
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
HOOD
+1.03%
$140.40
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
PFE
-0.30%
$24.70
RR
+7.85%
$6.38
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
IREN
+8.04%
$64.58
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
HOOD
+1.03%
$140.40
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.